May. 25 at 5:39 AM
$TNXP more info coming soon. There seems to be some confusion that i’m just a data guy; any joe schmoe could get the symphony numbers.
I specialize in identifying asymmetric biotech opportunities before broad institutional consensus forms, with a focus on commercialization inflections, payer access, launch trajectory analysis, and valuation dislocations. My framework combines clinical understanding with real-world commercial metrics like script trends, GTN dynamics, PBM/formulary expansion, cash runway, and operating leverage.
I’ve been early on names across both commercial-stage and clinical-stage biotech, including, CELG, TNXP,
$NUVB ,
$INSM ,
$URGN , ALT, and others, using a data-driven approach centered on identifying when the market is underestimating adoption velocity and long-term revenue potential.
I plan on sharing free regular info on here to drive awareness- but I have an LLC and can help navigate the storm, why not use it? 🤔
